These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37076093)

  • 1. Rationale, current state and opportunities in combining biologic disease modifying antirheumatic drugs in rheumatoid and psoriatic arthritis.
    Mutlu MY; Tascilar K; Schett G
    Joint Bone Spine; 2023 Sep; 90(5):105578. PubMed ID: 37076093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial).
    Uhrenholt L; Schlemmer A; Hauge EM; Christensen R; Dreyer L; Suarez-Almazor ME; Kristensen S
    BMJ Open; 2019 Jul; 9(7):e028517. PubMed ID: 31292181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of biologic and target synthetic disease-modifying anti-rheumatic drugs on sarcopenia in spondyloarthritis and rheumatoid arthritis: a systematic review and meta-analysis.
    Ben Tekaya A; Mehmli T; Ben Sassi M; Teyeb Z; Bouden S; Rouached L; Mahmoud I; Dziri C; Abdelmoula L
    Clin Rheumatol; 2023 Apr; 42(4):979-997. PubMed ID: 36462127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register.
    Lie E; Fagerli KM; Mikkelsen K; Rødevand E; Lexberg A; Kalstad S; Uhlig T; Kvien TK
    Ann Rheum Dis; 2014 Oct; 73(10):1905-6. PubMed ID: 24989896
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.
    Shan J; Zhang J
    Joint Bone Spine; 2019 Mar; 86(2):173-183. PubMed ID: 29635017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study.
    Mena-Vazquez N; Manrique-Arija S; Yunquera-Romero L; Ureña-Garnica I; Rojas-Gimenez M; Domic C; Jimenez-Nuñez FG; Fernandez-Nebro A
    Rheumatol Int; 2017 Oct; 37(10):1709-1718. PubMed ID: 28631046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Useful message in choosing optimal biological agents for patients with autoimmune arthritis.
    Lai JH; Ling XC; Ho LJ
    Biochem Pharmacol; 2019 Jul; 165():99-111. PubMed ID: 30876919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis.
    So A; Inman RD
    Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):453-471. PubMed ID: 31171315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis.
    Min HK; Kim SH; Kim HR; Lee SH
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing.
    Pontifex EK; Dissanayake K; Bursill D; Gill T
    Int J Rheum Dis; 2019 Feb; 22(2):262-268. PubMed ID: 30450819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff.
    Alves de Oliveira Junior H; Pereira da Veiga T; Acurcio FA; Almeida AM; Ribeiro Dos Santos JB; da Silva MRR; Kakehasi AM; Cherchiglia ML
    Hosp Pract (1995); 2020 Oct; 48(4):213-222. PubMed ID: 32567403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose reduction of biologic therapy in inflammatory arthritis: A qualitative study of patients' perceptions and needs.
    Hewlett S; Haig-Ferguson A; Rose-Parfitt E; Halls S; Freke S; Creamer P
    Musculoskeletal Care; 2019 Mar; 17(1):63-71. PubMed ID: 30398699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib.
    Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A; Reyes JM; Gamboa NC
    Clin Rheumatol; 2021 Apr; 40(4):1273-1281. PubMed ID: 32997316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study.
    Maeda Y; Hirano T; Ebina K; Hara R; Hashimoto M; Yamamoto W; Murakami K; Kotani T; Hata K; Son Y; Amuro H; Onishi A; Jinno S; Katayama M; Kumanogoh A
    Rheumatol Int; 2021 Jul; 41(7):1233-1241. PubMed ID: 33903963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry.
    Prior-Español A; Sánchez-Piedra C; Campos J; Manero FJ; Pérez-García C; Bohórquez C; Busquets-Pérez N; Blanco-Madrigal JM; Díaz-Torne C; Sánchez-Alonso F; Mateo L; Holgado-Pérez S
    Sci Rep; 2021 May; 11(1):11091. PubMed ID: 34045525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.
    Bengtsson K; Jacobsson LT; Rydberg B; Kvist G; Torstenson T; Dehlin M; Hilme E; Lindhé A; Wallerstedt SM; Forsblad-d'Elia H
    BMC Musculoskelet Disord; 2016 Dec; 17(1):499. PubMed ID: 27955647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Biggioggero M; Benucci M; Li Gobbi F; Grossi V; Infantino M; Meacci F; Manfredi M; Guiducci S; Bellando-Randone S; Matucci-Cerinic M; Foti R; Di Gangi M; Mosca M; Tani C; Palmieri F; Goletti D;
    Semin Arthritis Rheum; 2016 Apr; 45(5):519-32. PubMed ID: 26607440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis.
    Favalli EG; Matucci-Cerinic M; Szekanecz Z
    Autoimmun Rev; 2020 Jan; 19(1):102421. PubMed ID: 31733368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.
    Nandi P; Kingsley GH; Scott DL
    Curr Opin Rheumatol; 2008 May; 20(3):251-6. PubMed ID: 18388514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.